Thus, we next characterized the susceptibility of a set of human cancer cells (Table S2, Supplementary Material) with either oncogenic KRAS mutations or a BRAFV600E mutation to MEK1/2 inactivation mediated by LF-W271A. The gene discussed is KRAS; the disease is cancer.